F. L. Meyskens

1.8k total citations
23 papers, 1.4k citations indexed

About

F. L. Meyskens is a scholar working on Molecular Biology, Biochemistry and Oncology. According to data from OpenAlex, F. L. Meyskens has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 5 papers in Biochemistry and 4 papers in Oncology. Recurrent topics in F. L. Meyskens's work include Retinoids in leukemia and cellular processes (7 papers), Amino Acid Enzymes and Metabolism (5 papers) and Polyamine Metabolism and Applications (5 papers). F. L. Meyskens is often cited by papers focused on Retinoids in leukemia and cellular processes (7 papers), Amino Acid Enzymes and Metabolism (5 papers) and Polyamine Metabolism and Applications (5 papers). F. L. Meyskens collaborates with scholars based in United States and United Kingdom. F. L. Meyskens's co-authors include Eugene W. Gerner, Polly Feigl, Carol M. Moinpour, Kavitha Prasad, Barbara Metch, Katherine Hayden, John M. Crowley, D S Alberts, Laura Lovato and Grant N. Stemmerman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Journal of Urology.

In The Last Decade

F. L. Meyskens

22 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. L. Meyskens United States 13 583 534 226 167 150 23 1.4k
Julie Beitz United States 20 697 1.2× 493 0.9× 78 0.3× 127 0.8× 156 1.0× 39 2.0k
Rebecca B. Rosenstein United States 13 245 0.4× 324 0.6× 108 0.5× 157 0.9× 192 1.3× 26 1.3k
Huiyun Wu United States 20 411 0.7× 356 0.7× 71 0.3× 203 1.2× 270 1.8× 55 1.7k
Gregory Sarna United States 18 268 0.5× 369 0.7× 142 0.6× 197 1.2× 188 1.3× 44 1.2k
Basil A. Stoll United Kingdom 21 348 0.6× 627 1.2× 134 0.6× 113 0.7× 99 0.7× 92 1.5k
Arthur D. Schwabe United States 19 839 1.4× 353 0.7× 159 0.7× 209 1.3× 516 3.4× 45 1.9k
Stephen I‐Hong Hsu United States 22 416 0.7× 337 0.6× 62 0.3× 112 0.7× 127 0.8× 39 1.5k
J. H. P. Wilson Netherlands 28 839 1.4× 263 0.5× 160 0.7× 536 3.2× 345 2.3× 93 2.2k
Susan Kune Australia 22 230 0.4× 924 1.7× 476 2.1× 204 1.2× 257 1.7× 30 1.9k
Hakan Akbulut Türkiye 23 394 0.7× 674 1.3× 86 0.4× 278 1.7× 146 1.0× 138 1.7k

Countries citing papers authored by F. L. Meyskens

Since Specialization
Citations

This map shows the geographic impact of F. L. Meyskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. L. Meyskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. L. Meyskens more than expected).

Fields of papers citing papers by F. L. Meyskens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. L. Meyskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. L. Meyskens. The network helps show where F. L. Meyskens may publish in the future.

Co-authorship network of co-authors of F. L. Meyskens

This figure shows the co-authorship network connecting the top 25 collaborators of F. L. Meyskens. A scholar is included among the top collaborators of F. L. Meyskens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. L. Meyskens. F. L. Meyskens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zell, Jason A., et al.. (2010). Ornithine Decarboxylase-1 Polymorphism, Chemoprevention With Eflornithine and Sulindac, and Outcomes Among Colorectal Adenoma Patients. JNCI Journal of the National Cancer Institute. 102(19). 1513–1516. 24 indexed citations
2.
Zell, Jason A., Cheryl L. Rock, Christine E. McLaren, et al.. (2010). Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas.. Journal of Clinical Oncology. 28(15_suppl). 1523–1523. 2 indexed citations
3.
Zell, Jason A., Christine E. McLaren, Eugene W. Gerner, & F. L. Meyskens. (2008). Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo. Journal of Clinical Oncology. 26(15_suppl). 1502–1502. 3 indexed citations
4.
Simoneau, Anne R., et al.. (2001).  -Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial. JNCI Journal of the National Cancer Institute. 93(1). 57–59. 29 indexed citations
5.
Meyskens, F. L.. (2000). Criteria for implementation of large and multiagent clinical chemoprevention trials. Journal of Cellular Biochemistry. 77(S34). 115–120. 9 indexed citations
6.
Meyskens, F. L.. (2000). Cancer population genetics and tumour prevention. European Journal of Cancer. 36(10). 1189–1192. 3 indexed citations
7.
Meyskens, F. L. & Eugene W. Gerner. (1999). Development of difluoromethylornithine (DFMO) as a chemoprevention agent.. PubMed. 5(5). 945–51. 278 indexed citations
8.
Moinpour, Carol M., Andrea B. Troxel, Laura Lovato, et al.. (1999). Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. The Journal of Urology. 161(4). 1394–1395. 22 indexed citations
9.
Ahnen, Dennis J., Polly Feigl, Cecilia M. Fenoglio‐Preiser, et al.. (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.. PubMed. 58(6). 1149–58. 279 indexed citations
10.
Meyskens, F. L., Earl A. Surwit, Thomas E. Moon, et al.. (1994). Enhancement of Regression of Cervical Intraepithelial Neoplasia II (Moderate Dysplasia) With Topically Applied All- trans -Retinoic Acid: a Randomized Trial. JNCI Journal of the National Cancer Institute. 86(7). 539–543. 199 indexed citations
11.
Meyskens, F. L.. (1994). Retinoids for the management of human cancer: discovered and rediscovered.. 367–383. 1 indexed citations
12.
Garewal, H S & F. L. Meyskens. (1991). Beta-Carotene Didn't Prevent Cancer: What's Up Doc?. JNCI Journal of the National Cancer Institute. 83(15). 1111–1111. 1 indexed citations
13.
Aickin, Mikel, et al.. (1991). Dose-Related α-Difluoromethylornithine Ototoxicity. American Journal of Clinical Oncology. 14(4). 331–335. 24 indexed citations
14.
Moinpour, Carol M., Polly Feigl, Barbara Metch, et al.. (1989). Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations. JNCI Journal of the National Cancer Institute. 81(7). 485–496. 311 indexed citations
15.
Yohem, Karin H., Marvin D. Bregman, & F. L. Meyskens. (1987). Effect of tumor colony definition on ionizing radiation survival curves of melanoma-colony forming cells. International Journal of Radiation Oncology*Biology*Physics. 13(11). 1725–1733. 9 indexed citations
16.
Meyskens, F. L. & Kedar N. Prasad. (1986). Vitamins and Cancer: Human Cancer Prevention by Vitamins and Micronutrients. Medical Entomology and Zoology. 20 indexed citations
17.
Greenberg, Bernard R., et al.. (1985). Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.. PubMed. 69(12). 1369–74. 42 indexed citations
18.
Meyskens, F. L. & Kavitha Prasad. (1983). Modulation and mediation of cancer by vitamins. KARGER eBooks. 105 indexed citations
19.
Persky, Bruce, et al.. (1983). Scanning and transmission electron microscopic evaluation of human melanoma cells treated with adriamycin and actinomycin D.. PubMed. 983–95. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Beitz Breakdown of academic impact, for papers by Rebecca B. Rosenstein Breakdown of academic impact, for papers by Huiyun Wu Breakdown of academic impact, for papers by Gregory Sarna Breakdown of academic impact, for papers by Basil A. Stoll Breakdown of academic impact, for papers by Arthur D. Schwabe Breakdown of academic impact, for papers by Stephen I‐Hong Hsu Breakdown of academic impact, for papers by J. H. P. Wilson Breakdown of academic impact, for papers by Susan Kune Breakdown of academic impact, for papers by Hakan Akbulut
Rankless by CCL
2026